REG - Celadon Pharma. PLC - Funding Update, Notice of AGM

Celadon PharmaceuticalsAnnouncement

Yesterday 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250606:nRSF8740La&default-theme=true

RNS Number : 8740L  Celadon Pharmaceuticals PLC  06 June 2025

Celadon Pharmaceuticals Plc

("Celadon", the "Group" or the "Company")

Funding Update

Notice of AGM

London, 6 June 2025 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the development, production and sale of
breakthrough cannabis-based medicines, provides an update on its financial
position.

Funding Update

The Company announced on 30 May 2025 that in the event the Company cannot
secure funds over the coming days, the directors would have to protect the
interests of all stakeholders and the Company will be placed into
administration.

The Company continues to be engaged with a new finance provider who has
concluded due diligence and who has indicated he is in the process of making
funds available.

As of today, the Company continues to have limited working capital and its
ability to continue to trade is fully dependent upon receiving funds from the
new finance provider and continued creditor and stakeholder support. In the
event the Company cannot secure funds during the course of the next week, the
directors will have to protect the interests of all stakeholders and the
Company will be placed into administration.

In the event funding for the Group is secured, the Company remains committed
to proceeding with a cancellation of trading of the Company's ordinary shares
on AIM.

Notice of Annual General Meeting

The Company's Annual General Meeting ("AGM") will be held at The Aston Tavern
Hotel, 10 Aston Hall Road, Birmingham, B6 7FF on 30 June 2025 at 12 noon. The
notice of AGM (the "Notice of AGM") will shortly be available from the
Company's website at https://celadonpharma.com/meetings/ and posted to
shareholders shortly, together with the form of proxy. In accordance with the
Companies Act, the Company is required to hold an AGM within six months of the
end of its financial year. A resolution to approve the Company's report &
accounts will not be tabled as a resolution at the AGM.

A further announcement will be made as and when appropriate.

 

Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                                                                           Via Canaccord Genuity Limited

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts                                                                         +44 (0)20 7523 8000

 Global Investment Strategy UK Limited (Joint Broker)                                                  +44 (0)20 7048 9400

 James
 Sheehan

 

About Celadon Pharmaceuticals Plc

 

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on
the development, production and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain sufferers,
as well as exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved
and comprises indoor hydroponic cultivation, proprietary GMP extraction and an
analytical and R&D laboratory. Celadon's Home Office licence allows for
the commercial supply of its pharmaceutical-grade cannabis product. The Group
owns an approved clinical trial using cannabis-based medicinal products to
treat chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics, which is developing a licensed
cannabinoid medicine to treat children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

 

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication
of this announcement, this information is now considered to be in the public
domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAEALKKESASEFA